/PRNewswire/ Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd..
Share this article
Share this article
REHOVOT, Israel, Jan. 21, 2021 /PRNewswire/ Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), today announced it will be featured as a presenting company at the Crohn s & Colitis Congress® to be held from today January 21-24, 2021.
Prof. Yehuda Ringel, CSO of Biomica, will present
BMC322 - A rationally-designed live bacterial consortium based on microbiome functional genomic analysis for treatment of IBD on Saturday 23
rd January, 2021 at 2PM (EST).
The Crohn s & Colitis Congress is jointly organized by the American Crohn s & Colitis Foundation (CCFA) and the American Gastroenterological Association (AGA). The Congress connects IBD providers and researchers from around the world and will be held virtually this year.